

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Anderson et al.

Appln. No.: 08/

Series Code ↑ 921,060

Filed: August 29, 1998

Hon. Commissioner of Patents
Washington, D.C. 20231 MAR 06 2003

Sir:

RECEIVED
TECH CENTER 1600
REPLY/AMENDMENT/LETTER

Group Art Unit 1644
Examiner: R. Schwadron
Atty. Dkt. P 0275463 | 1992-30-0029CP2
M# Client Ref

Appln. Title: EX VIVO TREATMENT OF
ALLOGENIC AND XENOGENIC
DONOR T CELLS CONTAINING
COMPOSITIONS (BONE MARROW)
USING GP39 ANTAGONISTS AND
USE THEREOF

Date: February 28, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim	For B & C See Required Separate Paper (Pat-256)
A. <input checked="" type="checkbox"/> NOT made	
B. <input type="checkbox"/> Withdrawn	
C. <input type="checkbox"/> made herewith	
D. <input type="checkbox"/> made previously	

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)	add		+ \$280/\$140 =	+ \$0		104/204
5. Original due Date: <input type="checkbox"/> NONE						
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo) (2 mos) (3 mos) (4 mos) (5 mos)	\$110/\$55 = \$410/\$205 = \$930/\$465 = \$1,450/\$725 = \$1,970/\$985 =	+ \$110			115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract		- \$0				
8.		Extension Fee	+ \$110			
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		+ \$110/\$55	+ \$0			148/248
10. If IDS attached requires Official Fee under Rule 97 (c), or if Rule 97(d) Request	add add	+ \$180 + \$180	+ \$0			126 126
11. After-Final Request Fee per rules 129(a) and 17(r)		+ \$750/370	+ \$0			146/246
12. No. of additional inventions for examination per Rule 129(b).....		x \$750/375 ea	+ \$0			149/249
13. Request for Continued Examination (RCE)		+ \$750/375	+ \$0			1179/1279
14. Petition fee for			+ \$0			
15.		TOTAL FEE =	\$ 110			
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".						
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.						
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.						

03/04/2003 CCHAU1 0000068 033975 08921060

Our Deposit Account No. 03-3975

(Our Order No. 037003 0275463

01 FC:1251 110.00 CH

C# M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin

Reg. No. 35,030

Sig: *Robin Teskin / Julie Broadbush* Fax: (703) 905-2500
47,447 Tel: (703) 905-2200

Atty/Sec: RLT/RLG

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



RECEIVED
FEB 28 2003
MAR 06 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Anderson et al.

Group Art Unit: 1644

Application Serial No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: *EX VIVO TREATMENT OF ALLOGENIC AND XENOGENDIC DONOR T CELLS CONTAINING COMPOSITIONS (BONE MARROW) USING GP39 ANTAGONISTS AND USE THEREOF*

* * * * *

ELECTION RESPONSE

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Restriction Requirement] mailed on December 30, 2002, Applicants elect for purposes of examination with traverse the following:

- (1) the antibody heavy SEQ ID NO. 11 and
- (2) a method of using the antibody to deplete B cells.

The restriction is traversed on the basis that methods of treating B cell lymphoma and methods of B cell depletion will be substantially co-extensive, as will the search for only two different chemical antibody sequencers. Rejoinder is therefore requested.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Robin Teskin / Julie Broadus
Robin L. Teskin
Registration No. 35,030

47,447

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: February 28, 2003
Attorney Reference: 037003-0275463
/rg